Leah Brownlee, J.D. has been appointed as President and General Counsel of Indago, a Cleveland, Ohio-based medical device and technology company. Brownlee most recently served in the Corporate Practice and Life Sciences Industry groups at Squire Patton Boggs and previously worked as Executive Vice President of Compliance and Operations at Cleveland BioLabs, Inc., a clinical-stage NASDAQ-listed biotechnology company (CBLI).
Leah Brownlee—New President, General Counsel at Indago
1 min read Premium comments
Secondary#indago#leahbrowniee
Brownlee begins her role as the company ramps up plans to create the operating room of the future with a smart platform for a highly efficient, tech-enabled surgical suite.
“We couldn’t be happier to have Leah join the management team as Indago proceeds through the final stages of product development, regulatory approval, and commercial launch for its ArthroFree wireless arthroscopic camera system,” said Mark Froimson, M.D., Chairman of the Board.
“Leah’s vast experience in the life sciences sector, along with her leadership roles across public and private companies, makes her the ideal person to join Indago as we approach the marketing approval and launch of the ArthroFree system,” said Eugene Malinskiy, Chief Executive Officer.
Commenting on her time to date at Indago, Brownlee told OTW, “My first steps in my new role have been to work with Eugene and the Indago team as we focus on hitting the critical milestones ahead on the path to bringing ArthroFree to market.”
It is worth noting that Indago has attracted some of the most senior and experienced managers and investors in orthopedics. Dr. Froimson, in addition to his duties at Indago, also serves as Chief Medical Officer for AngelMD, is a board member for Pacira Biosciences and SINTX Technologies and was the former Executive Vice President and Chief Clinical Officer for Trinity Health. Also serving as Indago’s board member is Gary Cohn, formerly Director of the United States National Economic Council and a former Goldman Sachs senior partner.
Jon Serbousek, Chief Executive Officer with Orthofix and former Senior Vice President and Officer of Biomet is also a member of Indago’s board of directors. Finally, Jeff Hanson, who was a founding member of Milestone Capital, is, like Mr. Cohn, a former executive with The Goldman Sachs Group.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.